Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings
TRVI·Reported May 5, 2026·After market close
Diluted EPS came in at $-0.09 (+0.0% YoY), missed the $-0.07 consensus by $0.02.
Diluted EPS
$-0.09missed by $0.02
Consensus: $-0.07
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Trevi Therapeutics, Inc.'s Q1 2026 earnings report.
Trevi Therapeutics, Inc. (TRVI) reported Q1 2026 earnings on May 5, 2026 after market close.
Trevi Therapeutics, Inc. reported diluted EPS of $-0.09 for Q1 2026.
EPS missed the consensus estimate of $-0.07 by $0.02.
Compared to the same quarter a year prior, diluted EPS grew 0.0% from $-0.09.
You can read the 8-K earnings release (0001193125-26-206382) and the 10-Q periodic report (0001193125-26-206390) directly on SEC EDGAR. The filing index links above go to sec.gov.